Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
67 participants
OBSERVATIONAL
2020-02-21
2023-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The fracture of the upper end of the femur (EFSF) is a pathology:
* Frequent, affecting the elderly: in France, 80,000 patients / year, 83% aged ≥ 75 years (DREES, 2011),
* severe, on mortality and autonomy: 40% will not recover their walking capacity earlier than 6 months, 13% of patients \> 85 years old walk unaided at 4 months and 11% of patients will be newly admitted to an institution in 6 months after the fracture (UPOG / PSL data).
* and costly: costs related to acute care (excluding prostheses and osteosynthesis equipment), are estimated at € 475 million for health insurance in France.
Currently, despite optimized orthogeriatric management, it is difficult to predict how the individual will respond / recover from acute stress related to the EFSF. Physical resilience is an emerging concept in medicine that defines the dynamic ability of a subject to resist or recover from functional decline as a result of stress or disruption. In this context, developing new approaches to assessing resilience is important, to take into account this resilience specific to each patient in order to develop a personalized functional rehabilitation strategy. The objective of the HIPRESM study is to be able to identify, in elderly patients after an EFSF intervention, the muscular signature associated with good functional recovery (= physical resilience). The goal of the investigators is to develop software that will provide this muscle signature by measuring and analyzing parameters from high-definition surface electromyography (HD-sEMG). This technology is innovative, non-invasive and portable, CE marked but not yet used in clinical routine.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The upper femoral fracture (UFF) is a common pathology: in France, it concerns nearly 80.000 patients per year, 83% of whom are aged 75 (DREES, 2011).
The UFF is a pathology with serious consequences, on the mortality but also on the functional level, since 40% of the patients will not recover their walking capacity previous to 6 months, only 13% of the patients over 85 years old will walk unaided to 4 months and 11% of patients will be newly admitted to an institution within 6 months of the fracture (UPOG data, 20% for patients with major neurocognitive disorders, 4% for others). In the literature, at least 25% of elderly people will not recover their previous walking ability, especially for transfers, walking and climbing stairs (Alarcon 2011, Arinzon 2010, Visser 2000).
The UFF is an expensive pathology, whose costs related to acute care (excluding prostheses and osteosynthesis equipment), are estimated at € 475 million in health insurance in France.
Currently, despite optimized orthogeriatric management, it is difficult to predict how the individual will respond/recover from acute UFF-related stress. Physical resilience is an emerging concept in medicine, which defines the dynamic ability of a subject to resist or recover from a functional decline due to stress or disruption. In this context, developing new approaches to assess resilience is important, to take into account each patient's specific resilience in order to develop a personalized functional rehabilitation strategy. The objective of the HIPRESM study is to identify, in older patients after a UFF intervention, the muscle signature associated with good functional recovery (= physical resilience). The objective of the investigators is to identify the parameters derived from high definition surface electromyography (HD-sEMG) by developing software that will provide this muscle signature. This technology is innovative, non-invasive and portable, and already CE marked.
Main objective: to identify HD-sEMG parameters, measured during quadriceps extension of the lower limb not affected by surgery, within 7 days post surgery for UFF, associated with functional status without human assistance (SPPB) at day 30.
Main Evaluation Criterion: To investigate the association between the parameters provided by HD-sEMG (32 simultaneous channels; portable device and software, Mobita®) of the rectus femoris and functional status without human assistance measured by the Short Physical Performance Battery (SPPB = walking speed over 4 meters, chair satnds, balance) at 30 days after surgery for FESF.
Secondary objectives: to study the association between parameters from HD-sEMG measured during quadriceps extension of the lower limb not affected by surgery within 7 days post surgery for FESF and :
1. the walking capacity at D30
2. the autonomy at D30
3. the walking speed over 5m at D30
4. the quality of life on D30
5. the evolution of HD-sEMG muscle quality at D30
6. in-hospital mortality and at D30
7. the time required for rehospitalization
8. the average length of stay in Follow-up Care and Rehabilitation and in the orthogeriatric stream
Secondary evaluation criteria:
1. Walking ability without human assistance: autonomous walking, with technical assistance, impossible, at D30
2. Autonomy measured by the ADL scale at D30
3. Walking speed over 5 meters at D30
4. Quality of life assessed by the EQ5D questionnaire at D30
5. HD-sEMG settings at D30
6. Death in hospital and at D30
7. The time required for rehospitalization
8. The average length of stay in rehabilitation and orthogeriatric care
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High definition surface electromyography (HD-sEMG)
HD-sEMG data will be collected by Mobita 32® (TMSi) device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Managed by orthogeriatric unit after upper femoral fracture surgery
* Patient informed of the study and who has not objected to his participation.
Exclusion Criteria
* Any other associated fracture
* Cutaneous allergy with adhesive plaster
* BMI ≥ 30 kg / m²
* Cognitive disorders preventing the correct execution of the movement
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université de Technologie de Compiegne
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
KIYOKA KINUGAWA, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
APHP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
APHP - Charles Foix Hospital
Ivry-sur-Seine, , France
APHP - Rotschild
Paris, Île-de-France Region, France
APHP - Saint-Antoine Hospital
Paris, Île-de-France Region, France
APHP - Pitie Salpetriere Hospital - UPOG
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-A00770-57
Identifier Type: OTHER
Identifier Source: secondary_id
APHP180486
Identifier Type: -
Identifier Source: org_study_id